Balarama Gundapaneni

Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy

Jeffrey H. Schwartz, Balarama Gundapaneni, Perry Elliott et al. · New England Journal of Medicine · 2018 · 2.7K citations · Full text

Medicine, Cardiology, Pharmacotherapy +13

Efficacy and safety of tafamidis doses in the <scp>Tafamidis in Transthyretin Cardiomyopathy Clinical Trial</scp> ( <scp>ATTR‐ACT</scp> ) and long‐term extension study

Thibaud Damy, Pablo García‐Pavía, Mazen Hanna et al. · European Journal of Heart Failure · 2020 · 208 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy

Perry Elliott, Brian Drachman, Stephen S. Gottlieb et al. · Circulation Heart Failure · 2021 · 193 citations · Full text

Pharmacy, Cardiology, Pharmacotherapy +13

Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy

Claudio Rapezzi, Perry Elliott, Thibaud Damy et al. · JACC Heart Failure · 2020 · 119 citations · Full text

Medicine, Cardiology, Genetics +9

Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy

Márcia Waddington‐Cruz, Leslie Amass, Denis Keohane et al. · Amyloid · 2016 · 103 citations · Full text

Pharmacy, Neurology, Pharmacotherapy +14